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Abstract
Background: Diffuse large B cell lymphoma (DLBCL) is the most common type of lymphoid malignancy
worldwide. Approximately 5 % of cases of DLBCL are so-called double-hit lymphomas (DHL), defined by a
chromosomal translocation or rearrangement involving MYC/8q24.2 in combination with another recurrent
breakpoint, usually BCL2/18q21.3. Patients with MYC/BCL2 DHL are resistant to standard front-line therapy, and
currently, there is no consensus for a therapeutic strategy to treat these patients. Lack of clinically relevant or
validated human experimental DHL models of any type that would improve our understanding of the biologic
basis of MYC/BCL2 DHL pathophysiology continues to hamper identification of valid therapeutic targets. We
describe a unique MYC/BCL2 DHL cell line with morphologic features of DLBCL that we have established,
designated as RC.
Methods: We used tissue culture techniques to establish the RC cell line from primary DLBCL cells. We also utilized
molecular and cellular biological techniques including flow cytometry, polymerase chain reaction (PCR), DNA
fingerprinting, reverse-phase protein array, conventional cytogenetics, and fluorescence in situ hybridization (FISH)
analysis to characterize the RC cell line. NSG-severe combined immunodeficiency (SCID) mice were utilized as a
model for xeno-transplantation of RC cells.
Results: RC cells had the following immunophenotype: positive for CD10, CD19, CD20, CD22, CD38, CD43, CD44,
and CD79b and negative for CD3, CD4, CD5, CD8, CD11c, CD14, CD30, CD56, and CD200, which was identical to
the primary tumor cells. Conventional cytogenetic analysis showed a t(2;8)(p12;q24.2) and t(14;18)(q32;q21.3),
corresponding to MYC and BCL2 gene rearrangements, respectively. DNA fingerprinting authenticated the RC cell
line to be of the same clone as the primary tumor cells. In addition, RC cells were established in SCID mice as an in
vivo model for translational therapeutics studies. Proteomic analysis showed activation of the mTOR signaling
pathway in RC cells that can be targeted with an mTOR inhibitor.
Conclusion: The data presented confirm the validity of the RC cell line as a representative model of MYC/BCL2 DHL
that will be useful for both in vitro and in vivo studies of DHL pathogenesis and therapeutics.
Keywords: Double-hit lymphoma (DHL), DLBCL, RC cell line, MYC, BCL2
* Correspondence: lvpham@mdanderson.org
Department of Hematopathology, The University of Texas MD Anderson
Cancer Center, 1515 Holcombe Blvd. Unit 54, Houston, TX 77030, USA
JOURNAL OF HEMATOLOGY
& ONCOLOGY
© 2015 Pham et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Pham et al. Journal of Hematology & Oncology  (2015) 8:121 
DOI 10.1186/s13045-015-0218-1
Background
Diffuse large B cell lymphoma (DLBCL) is the most
common type of non-Hodgkin lymphoma worldwide. In
the USA, DLBCL represents approximately 30 % of all
new lymphoma cases per year and is the fifth most com-
mon cancer [1]. Current standard front-line therapy for
DLBCL patients involves rituximab immunotherapy and
cyclophosphamide, doxorubicin, vincristine, and pred-
nisone (R-CHOP). Approximately 70–80 % of patients
experience some form of remission, but relapsed/re-
fractory DLBCL occurs in 30–40 % of patients within
2–3 years, and this patient subset has poor salvage
therapy options [1–4].
DLBCL is a molecularly heterogeneous disease [5, 6].
Approximately 30–40 % of cases of DLBCL are character-
ized by recurrent chromosomal translocations involving
BCL6/3q27, BCL2/18q21.3, and MYC/8q24.4 in about 30,
20, and 10 % of DLBCL cases, respectively. In recent years,
the concept of double-hit lymphoma (DHL) has received
much attention in the literature. DHL is defined by a
chromosomal breakpoint affecting the MYC/8q24.2 locus
in combination with another recurrent oncogene break-
point, usually BCL2 and less often BCL6 or rarely other
genes. MYC/BCL2 DHL represents approximately 70 % of
all cases of DHL. Double-hit lymphoma (all types) repre-
sents about 5 % of all cases of DLBCL and affected pa-
tients generally have an aggressive clinical course with
poor prognosis, despite combination chemotherapy, with
a median overall survival less than 1–2 years [7].
To date, exploratory studies to determine the pathogen-
esis of DHL have been limited, in part due to the lack of a
validated lymphoma cell model that is both immunophe-
notypically and genetically consistent with the original pri-
mary DHL tumor. To our knowledge, there have been
only a small number of published manuscripts demon-
strating the establishment and characterization of defined
DHL cell lines. The CJ cell line that we established in
1990 before recognition of the clinical importance of DHL
is believed to be the first DHL cell line showing both
MYC and BCL2 gene rearrangements [8]. In 2003, we
established another MYC/BCL2 DHL cell line, designated
EJ-1, that morphologically resembled DLBCL [9], and re-
cently, Hooper et al. [10] described the establishment of a
novel MYC/BCL2 DHL cell line, U-2973. Several recent
studies indicate that the OCI-LY18, Sc-1, and CARNA-
VAL DLBCL cell lines also appear to demonstrate MYC/
BCL2 double-hit characteristics [11, 12], but a compre-
hensive genetic analysis of these cell lines has not been
published. Collectively, these cell lines should provide
excellent models to study the pathophysiology and trans-
lational biology of MYC/BCL2 DHL. However, because
these cell lines were never genetically authenticated
against the primary tumor, the exact origin of these cells
remains unclear. Thus, additional, validated DHL cell lines
are a prerequisite for increasing our understanding and
therapeutic potential of DHL.
Herein, we described the establishment and
characterization of a novel MYC/BCL2 DHL cell line
with morphologic features of DLBCL, designated RC,
that closely shares an immunophenotype and cytogen-
etic features of the primary B cell tumor at diagnosis.
Results
Establishment of the RC cell line
Primary cells were obtained from a pleural effusion of a
patient diagnosed with diffuse large B cell lymphoma
with high-grade features (high mitotic activity and prolif-
eration rate). The primary cells were washed, explanted,
and cultured at approximately 5 × 106 cells/mL in RPMI-
1640 media, supplemented with 15 % fetal bovine serum
(FBS) without any external stimulation. The primary
cells remained viable (~90–95 %) even after 4 weeks in
cell culture; however, the number of cells remained con-
stant. During the fifth week in culture, cell number
began to increase and identifiable mitotic figures began
to appear. From this timepoint, the cells doubled in
number every 4–5 days. This established lymphoma cell
line successfully continued cell proliferation in a single-
cell suspension without cellular clump formation, grow-
ing in continuous culture for more than 16 months, and
aliquot samples could be frozen in medium composed of
90 % FBS and 10 % DMSO. The cell line was designated
as the “RC” cell line, optimally maintained at a density
between 1 and 2 × 106 cells/mL and could be split 1:2
every 3–4 days. RC cells are medium-to-large, blast-
like lymphoid cells, approximately 9–14 μm in largest
diameter (Fig. 1a) with moderately abundant strongly
basophilic cytoplasm. The nuclei were round to ovoid
with coarse chromatin and occasional irregular nu-
clear contours. The morphologic features of RC cells
were stable and did not change during 16 months in
culture (Fig. 1b).
EBV status in RC cells
The RC cells were shown to be negative for Epstein-Barr
virus (EBV) by polymerase chain reaction (PCR) analysis.
Epstein-Barr viral genomes (types 1 and 2) were de-
tected in the immortalized Granta MCL cell line (posi-
tive control) but not in the MCL Mino cell lines
(negative control) as expected (Fig. 1c).
Immunophenotypic characterization of RC cells by flow
cytometry
We performed flow cytometry immunophenotypic ana-
lysis on the original pleural effusion sample and later on
the established RC cell line after 12 months of continu-
ous culture. The immunophenotypes of the primary
tumor cells and RC cells were virtually identical
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(Table 1). RC cells are positive for CD10, CD19, CD20
(small subset), CD22, CD23, CD38, CD43, CD44 (par-
tial), CD45, and CD79b and are negative for CD3, CD4,
CD5, CD8, CD11c, CD14, CD30, CD200, or surface
kappa and lambda light chains. Representative flow cy-
tometry histograms showing that 99 % of RC cells are
positive for CD10, CD19, and CD79b, with no staining
for surface kappa and lambda light chains are shown
(Fig. 2). However, the presence of surface CD79b im-
plies surface immunoglobulin expression and there-
fore suggests that RC cells express an Ig light chain
that was not detectable by our standard anti-kappa or
anti-lambda monoclonal reagents. The original effu-
sion cells showed no staining for CD20, possibly due
to blockade by recently administered rituximab (anti-




Fig. 1 Morphologic and phenotypic features of RC cells. a Distribution of the size (longest diameter) of RC cells after 16 months of cell culturing.
b Representative image of H&E-stained RC cells after 16 months in cell culture. c PCR analysis for EBV type 1 (EBNA1) and type 2 (EBNA2) gene in
Mino (negative control), Granta (positive control), and RC cell lines. GAPDH serves as a loading control
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expression of CD20 (compared with normal mature B
cells), possibly due to selection of primary lymphoma
cells with low expression. Alternatively, dim or absent
CD20 expression has been reported in cases of DHL
by others [13]. RC cells also express a high level of
CD38, an indicator of MYC rearrangement [14].
Conventional cytogenetics and FISH analysis
Conventional cytogenetic analysis of RC cells revealed
a complex karyotype, including a t(2;8)(p12;q24.2) and
a t(14;18)(q32;q21.3) (Fig. 3a). The karyotype of RC
cells is similar to, but more complex than, the karyo-
type of the primary lymphoma cells (Table 2). How-
ever, only 15 metaphases were available for analysis of
the primary tumor cells. Interphase fluorescence in
situ hybridization (FISH) analysis with FISH mapback
performed on the RC cells showed multiple copies of
IGH/BCL2 fusion gene (Fig. 3b) and an allelic MYC
rearrangement most likely involving the IGK gene
mapped to 2p12 region (Fig. 3c) and corroborating
the t(2;8)(p12;q24.2) identified by conventional cyto-
genetic analysis (Fig. 3a). RC cells were negative for
IGH/MYC and IGH/CCND1 fusions as assessed by
FISH (data not shown).
STR DNA fingerprinting analysis of primary cells and RC
cells
Using a multiplex short tandem repeat (STR) DNA fin-
gerprinting system, which allows for the detection of
unique DNA fingerprints through the genotyping of 16
STR loci, primary lymphoma cells and the RC cells
shared 100 % identity. These results confirm that the
genetic parentage of RC cells is, in fact, the patient’s
lymphoma cells (Table 3). The RC cell line profile did
not match any other cell line profile in the current data-
base at MD Anderson Cancer Center or elsewhere.
Xeno-transplantation of RC cells into SCID mice
We inoculated RC cells by intraperitoneal (IP) injection
into the lower abdomen of five severe combined im-
munodeficiency (SCID) mice. Within 5 weeks, all five
(100 %) mice developed a solid tumor mass in the lower
abdomen (Fig. 4a). Further analysis showed that the
excised tumor mass was composed of lymphoid cells
(Fig. 4b) of human B cell origin, CD20 positive with char-
acteristic CD20 cell membranous expression (Fig. 4c),
morphologically consistent with RC cells.
Reverse-phase protein array (RPPA) analysis and response
to an mTOR inhibitor
We performed RPPA analysis on the RC cell line and
three additional DLBCL cell lines to determine the pro-
tein signaling profile of RC cell line. After quality control
analysis, expression data for 285 proteins were available
for further analysis. Supervised hierarchical clustering of
the data for all proteins showed a set of up-regulated
and down-regulated proteins in the RC cell line that dif-
fered from the other three DLBCL cell lines (Fig. 5a).
Based on the RPPA data, a diagram model was con-
structed showing activation of the integrin-MEK-ELK1
and the insulin-AKT-mTOR signaling pathways as being
used prominently in RC cells (Fig. 5b).
We also used a small molecule inhibitor of mTOR
(AZD8055) to determine whether RC cells can respond to
this agent. As demonstrated in Fig. 6a, RC cells are highly
sensitive to AZD8055 in comparison to the other three
DLBCL cell lines. In addition, RC cells treated with
AZD8055 down-regulate protein expression of phosphor-
AKT and phosphor-mTOR that are low or absent in
AZD8055-resistant MZ cells (Fig. 6b). These findings indi-
cate that the RC cell line is an excellent model for identify-
ing potential therapeutic agents, targeting pathways like
the PI3K-ATK-mTOR survival pathway.
Discussion
Although others had reported cases of DLBCL with
MYC and BCL2 rearrangements previously [17–20],
Aukema and colleagues [16] in 2011 published an im-
portant review article that introduced the concept of
Table 1 Immunophenotype profile of primary DH-DLBCL cells
and RC cells as determined by flow cytometry
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− negative staining, + positive staining, +/− dim/partial staining
Pham et al. Journal of Hematology & Oncology  (2015) 8:121 Page 4 of 11
DHL. Aukema and colleagues defined DHL as a neo-
plasm characterized by a MYC rearrangement combined
with another genetic abnormality, such as BCL2, BCL3,
BCL6, or other genes. Currently, over 400 cases of DHL
have been reported in the literature, with the combin-
ation of MYC and BCL2 being, by far, the most com-
mon. These studies have shown that patients with
double-hit lymphoma associated with MYC/8q24.2 and
IGH-BCL2/t(14;18) have an aggressive disease, clinically
characterized by B type symptoms, advanced clinical
stage, a high International prognostic index (IPI), poor
response to standard front-line R-CHOP or more
aggressive therapies, and a very poor prognosis with a
median survival of 1–2 years [7, 21]. As a result of the
poor prognosis, DHL is currently a subject of intense
clinical and research interest because there is no consen-
sus therapeutic approach for these patients and the con-
ceptual/mechanistic basis underlying the DHL remains
unclear [15].
A major limitation to the successful treatment of patients
with MYC/BCL2 DHL is an improved understanding of
disease pathogenesis, mechanisms of chemotherapeutic re-
sistance, and knowledge of potential therapeutic targets for
which new therapies can be rationally designed. We sug-
gest that the RC cell line reported here is of interest and
will be a useful tool that will be helpful in contributing to
an improved understanding of MYC/BCL2 DHL. The RC
cell line has the advantage of having been well studied ini-
tially, with further relevant follow-up studies. Its derivation
from a patient with a DHL is clearly identified by STR ana-
lysis. The RC cells have usual morphologic features of
DLBCL and the MYC and BCL2 abnormalities are well
documented by conventional cytogenetic analysis and
fluorescence in situ hybridization (FISH). The MYC re-
arrangement involves IGK gene mapped at 2p12 region
corroborating the t(2;8)(p12;q24.2) identified by constitu-
tional cytogenetic analysis. RC cells have a germinal center
B cell immunophenotype, as is the case for almost all pub-
lished cases ofMYC/BCL2 DHL, and a complete immuno-
phenotype is shown by flow cytometry immunophenotypic
analysis. Similar to the original lymphoma cells, RC cells
showed dim/low CD20 expression. The molecular mecha-
nism(s) resulting in decreased expression of CD20 in RC
cells and in DHL are unclear and have not been explored
[13]. The decreased expression of CD20 in DHL suggests
that the use of second-generation monoclonal antibodies
targeting CD20 may be fruitful because these engineered
antibodies are reportedly more effective than rituximab in
inducing complement-dependent cytotoxicity, particularly
in tumors with decreased CD20 antigen density [22, 23].
Several general findings have emerged from recently
published DHL retrospective series [7]. These studies
a b
c d
Fig. 2 Immunophenotype of RC cells. Representative flow cytometric histograms of total RC cells. a RC cells are positive for CD19 and CD10;
b they are positive for CD79b, implying surface immunoglobulin expression; c they are positive for CD20 in only a small subset; d they stained
negative for both surface kappa and lambda Ig light chains
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show that patients with DHL often present with extrano-
dal disease, central nervous system (CNS) involvement
is more common, and higher international prognostic
index (IPI) scores. However, retrospective studies have
not been able to contribute to a deeper understanding of
DHL or provide clues to potential therapeutic targets
that would enable substantial progress in therapy. Using
RPPA analysis, we have identified at least two important
growth/survival pathways (integrin-MEK-ELK1 and the
insulin-AKT-mTOR) that are highly activated in RC
cells. RC cells are highly sensitive to small molecule in-
hibitors of the AKT-mTOR pathway. Although it has
already been shown that the PI3K/Akt/mTOR pathway
is highly active in many B cell malignancies, including
DLBCL [24], our study is the first to demonstrate the
activation of these growth/survival pathways in a repre-
sentative DHL-DLBCL cell line. However, a recent study
showed that the PI3K/mTOR inhibitor BEZ235 can
potentiate the activity of the HDAC inhibitor panobino-
stat in pre-clinical models of DLBCL, including DHL cell
lines with overexpression of bcl-2 and MYC [12], further
suggesting activation of Akt/mTOR activation in DHL.
Further studies in more DHL cell lines as well as pri-
mary cells are required to validate whether the integrin-
Table 2 Clonal cytogenetic abnormalities in lymphoma cells from primary bone marrow sample and from RC cell line
Karyotype






(p12;q24.2), −3,+4, add(6)(q23), +8,+11,t(11;15)(q13;q26), +12,+12,−13,
add(13)(q34), t(14;18)(q32;q21.3), +der(18)t(14;18)x1~2, +20,+21, psu
dic(21;1)(q22;p13)x2, +2~4mar[cp20]
Fig. 3 Conventional cytogenetics and FISH analysis of RC cells. a Representative karyotype of RC cells. Red arrows point to t(2;8)(p12;q24.2)
translocation, and blue arrows point to t(14;18)(q32;q21.3) translocation also showing an extra copy of der(18)t(14;18) in the karyotype. b FISH
analysis confirmed t(14;18) in RC cells. IGH/BCL2 dual-color, dual-fusion translocation probes were used. Green: probe for the immunoglobulin
heavy chain gene; red: probe for the BCL2 gene; yellow: IGH-BCL2 fusion gene signal. c FISH analysis of MYC gene rearrangement, showing one
red and one green on the der(8)t(2;8) and der(2)t(2;8), respectively
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MEK-ELK1 and the insulin-AKT-mTOR pathways are
commonly activated and can be targeted in DHL. Tar-
geting the PI3K/mTOR pathway as was shown in this
study is just one example of the utility of the RC cell line
in biomarker research and drug development. New
drugs, particularly targeted therapeutic agents [25–27],
are increasingly being developed and entered the clinic
in recent years. Therefore, a fully characterized MYC/
BCL2 DHL cell line with morphologic features of
DLBCL, like RC, will be valuable for researchers in iden-
tifying novel targets and pre-clinical screening studies of
novel therapies that potentially can benefit patients [28].
Although not a specific focus of this study, it seems
that the concept of DHL has some limitations. It appears
likely that disease and resistance mechanisms in MYC/
BCL2 DHL are likely to differ from MYC/BCL6 DHL
and therefore the designation of DHL is descriptive but
not sufficiently specific. Even with the most common
MYC/BCL2 DHL, one of our early cell lines, CJ, was
derived from an elderly woman with typical low-grade
follicular lymphoma, with the usual t(14:18)(q32;q21.3)
who was initially successfully treated with conventional
CHOP chemotherapy, achieving a remission lasting
several years. This patient subsequently relapsed with
aggressive MYC/BCL2 DHL with a complex karyotype
and multiple other uncharacterized cytogenetic abnor-
malities. Interestingly, this DHL did not show the ex-
pected DLBCL morphology but retained the grade 1
(centrocytic or small cleaved cell) morphology [7],
while clearly progressing from indolent to aggressive
phenotype both in vitro and in vivo (SCID XT). CJ cells
are not only DHL cells but also currently the only known
centrocytic cell line, with a unique pathophysiology,
suggesting that MYC/BCL2 DHL is heterogeneous
and may provide insights into pathophysiologic mecha-
nisms such as large cell transformation of follicular
lymphoma. Although we believe the RC cell line will
be an excellent experimental tool to study MYC/BCL2
double-hit lymphoma, other additional cell lines, for
example to study MYC/BCL6 double-hit lymphomas, will
also be needed to better understand these less common
DHL tumors.
In summary, in this study, we report the establishment
and characterization of a novel MYC/BCL2 DHL cell line
with morphologic features of DLBCL, RC, that immuno-
phenotypically and cytogenetically closely resembles the
a b
c
Fig. 4 Xeno-transplantation of RC cells into SCID mice. a Necropsy of a SCID mouse that received a transplant of RC cells. Arrow pointing to the
tumor mass. b H&E paraffin sections of the SCID peritoneal tumor bearing the RC tumor cells. c Immunohistochemical analysis of the
transplanted lymphoma from a SCID mouse showing the expression of CD20
Table 3 STR DNA fingerprinting of primary cells and RC cells
Sample STR Loci
AMEL CSF1PO D13S317 D16S539 D21S11 FGA THO1 TPOX
Primary cells X,Y 10,12 12 11 28,32.2 21,24 9,9.3 8,11
RC cells X,Y 10,12 12 11 28,32.2 21,24 9,9.3 8,11
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primary B cell tumor at diagnosis. We believe that the
newly characterized DHL cell line will provide useful in
vitro and in vivo models for translational and biological
studies related to human DHL, which is refractory to




The University of Texas MD Anderson Cancer Center
Satellite Tissue Bank provided the patient samples
used for these studies. With informed consent from
the patient, the collected primary cells were purified
from ascites by Ficoll centrifugation (Ficoll-Paque
Plus; GE Healthcare, Life Sciences, Piscataway, NJ),
washed in phosphate-buffered saline twice, and resus-
pended in RPMI 1640 (Life Technologies, Grand
Island, NY) containing 15 % heat-inactivated FBS,
2 mM glutamine, and 50 μg/mL gentamycin at a con-
centration of 5–10 × 106 cells/mL (40 mL) in 75-cm2
flasks. Cultures were maintained at 37 °C in a hu-
midified incubator with a 5 % CO2 atmosphere. The
medium was exchanged every 3–5 days depending on
the cell growth rate. The cells were examined daily
using an inverted microscope and counted weekly
with a standard hemocytometer using trypan blue dye
a
b
Fig. 5 Reverse-phase protein array analysis of RC-DHL cell line. a Supervised hierarchical clustering heatmap of 285 proteins demonstrating the
differential protein expression profile of RC cells in comparison to three representative non-DHL-DLBCL cell lines, MZ, LP, and BJAB. b Schematic
diagram showing the potential pathways activated in RC cells based on the RPPA analysis
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exclusion. No external growth factors or stimulatory
cytokines were added during the establishment of the
RC cell line.
Cell growth and viability assay
Cell viability was assessed using the CellTiter-Glo Lumi-
nescent Assay (Promega). Cells were plated in triplicates
at 1–2 × 104 cells/well in 96-well plate with increase
concentrations of AZD8055 (Selleckchem) in 100 μl
total volume. Cell viability was assessed at 72 h after
treatment.
Western blot analysis
Cell lysates were prepared and immunoblotted as previ-
ously described [29, 30].
Flow cytometry
Eight-color flow cytometry analysis was performed with
FACS Canto II instruments (BD Biosciences, San Jose,
CA) using commercially available reagents on patient
samples collected in ethylenediaminetetraacetic acid
(EDTA) or cell line cells in culture medium. The cell
population was gated using right-angle light scatter and
CD45 expression. The panel of monoclonal antibodies
used included those specific for CD3, CD4, CD5, CD8,
CD10, CD11c, CD19, CD20, CD22, CD23, CD30, CD34
CD38, CD43, CD44, CD45, CD56, CD200, and surface
kappa and lambda light chains. All antibodies were pur-
chased from BD Biosciences. Data were analyzed using
FCS Express software (De Novo Software, Los Angeles,
CA). Antigen expression was scored as positive based on
a significant shift in staining in comparison to a negative
autofluorescence (empty channel) control.
Conventional cytogenetic analysis
RC cells were stimulated with phytohemagglutinin for
72 h before conventional G-banded karyotyping was per-
formed with metaphase cells derived from tumor cell cul-
tures. Briefly, metaphase cells were obtained after
hypotonic treatment and fixation with 3:1 methanol-acetic
acid solution using automatic harvesting system. Cell sus-
pensions derived from the automatic harvesting system
were dropped onto cleaned slides. G-banding was per-
formed after the slides were dried at 60 °C overnight.
Chromosome analysis and karyotyping, after the use of
Genetix metaphase automatic scanning system, were per-
formed with the CytoVision system. Twenty metaphases
were fully analyzed as per standard protocols.
Fluorescence in situ hybridization (FISH) was per-
formed on interphase nuclei from the cell culture using
a dual-color, break apart MYC probe and IGH/BCL2
dual-color, dual-fusion translocation probes (Abbott
Molecular, Des Plaines, IL), as described previously. The
cutoff to define a positive result for rearrangement of
MYC, and IGH/BCL2 probe is 3.8 and 0.1 %, respect-
ively. A total of 200 interphase cells were analyzed.
Short tandem repeat DNA fingerprinting
Genomic DNA was isolated from the original tumor and
the RC cell line using a Qiagen DNA purification kit
(Valencia, CA). DNA fingerprinting of lymphoma cells
was performed by the Institutional Characterized Cell
Line core facility at MD Anderson using the STR
method. Short tandem repeats are regions of microsatel-
lite instability with defined tri- or tetra-nucleotide
repeats that are located throughout the chromosomes. A
a
b
Fig. 6 Effects of an ATP competitive mTOR inhibitor AZD8055 in RC
cells. a Cells from RC and three additional representative DLBCL cell
lines (MZ, LP, and BJAB) were treated with increasing concentrations of
AZD8055. Cell viability was assessed by the CellTiter-Glo Luminescent
Assay after 72 h of treatment. Graph shows data that is representative
of two independent experiments with triplicate wells for each drug
concentration. b RC cells were treated with the indicated AZD9055
concentrations for 24 h. MZ cells were used as a negative
control. RC cells treated with the AKT inhibitor MK-2206 were also used
as a control. Cell extracts were purified and immunoblot for p-AKT,
AKT, and p-mTOR. Actin was used a loading control
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PCR-based method using primers on non-repetitive
flanking regions to generate PCR products of different
sizes based on the number of repeats in the region was
performed; the size of the products was determined by
capillary electrophoresis. Extracted DNA was analyzed
using the Power Plex 16HS System from Promega
(Madison, WI). The relatedness of the original tumor
and the RC cell line was determined by comparing the
STR loci profiles of the respective samples.
Epstein-Barr virus PCR amplification
EBV genotyping was performed by PCR using genomic
DNA to amplify a common region of the EBNA1 and
EBNA2 gene using a PCR kit from Promega with the fol-
lowing set of primers: EBNA1-F: GGT AGA AGG CCA
TTT TTC CAC; EBNA1-R: CTC CAT CGT CAA AGC
TGC AC; EBNA2-F: CAG GTA CAT GCC AAC AAC
CTT; EBNA2-R: CCA ACA AAG ATT GTT AGT GGA
AT. The PCR cycling conditions were as follows: 95 °C
2 min, 40 cycles of 94 °C 1 min, 60 °C 90 s, 72 °C 4 min,
followed by 72 °C for 10 min [31]. The EBV-negative
Mino and the EBV-positive Granta mantle cell lymph-
oma cell lines were used as negative and positive con-
trols, respectively.
Xeno-transplant of RC cells in severed combined
immunodeficient (SCID) mice
All animal experiments were reviewed and approved by
the MD Anderson Institutional Animal Care and Use
Committee (IACUC). For in vivo studies, 6-week-old fe-
male immumodeficient NOD.Cg-PrkdcscidI12rg
tm1Wj1/SzJ
mice were purchased from Jackson Laboratories (Bar
Harbor, ME) and housed under specific pathogen-free
conditions at the SCID Mouse Barrier Facility at MD
Anderson. RC cells (10 × 106) were injected intraperito-
neally into the mice using a 27-gauge needle.
Reverse-phase protein array (RPPA)
The RPPA Core Facility at MD Anderson Cancer Center
performed the RPPA analysis and antibody validation
[32]. For total protein lysate preparation, media were re-
moved, and cells were washed twice with ice-cold
phosphate-buffered saline (PBS) containing complete
protease and PhosSTOPphosphatase inhibitor cocktail
tablets (Roche Applied Science, Mannheim, Germany)
and 1 mM Na3VO4. Lysis buffer (1 % Triton X-100, 50
mMHEPES (pH 7.4), 150 mM NaCl, 1.5 mM MgCl2,
1 mM EGTA, 100 mM NaF, 10 mM NaPPi, 10 %
glycerol, 1 mM PMSF, 1 mM Na3VO4, and 10 μg/mLa-
protinin). Samples were vortexed frequently on ice and
then centrifuged. Protein lysates were adjusted to a 1 μg/
μL concentration, and a serial dilution of five concentra-
tions was printed, with 10 % of the samples replicated
for quality control (2470 Arrayer; Aushon Biosystems)
on nitrocellulose-coated slides (Grace Bio-Labs). Immu-
nostaining was performed using a DakoCytomation-
catalyzed system and diaminobenzidine colorimetric
reaction. Slides were scanned on a flatbed scanner to
produce 16-bit tiff images. Spot intensities were analyzed
and quantified using Array-Pro Analyzer to generate
spot signal intensities. Relative protein levels for each
sample were determined by interpolation of each dilu-
tion curve from the “standard curve” constructed by a
script in R written Bioinformatics. All the data points
were normalized for protein loading and transformed to
linear values that can be used for bar graph. Normalized
linear value was transformed to log2 value, and then
median-centered for hierarchical cluster analysis and for
heatmap generation. The heatmap was generated in
Cluster 3.0 (http://cluster2.software.informer.com/3.0/)
as a hierarchical cluster using Pearson correlation and a
center metric. The resulting heatmap was visualized in
Treeview (http://rana.lbl.gov/EisenSoftware.htm) and
presented as a high resolution .bmp format. Two hun-
dred eighty-five unique antibodies and four secondary
antibody negative controls were analyzed.
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